EGRIFTA WRTM Dosing and Administration1,2

Once-weekly reconstitution for simpler daily administration

EGRIFTA WRTM is a once-daily subcutaneous injection. Key features include:

  • Once-daily dosing of 1.28 mg

  • Concentrated for small daily injection volumes (0.16 mL)

  • Stored at room temperature (no refrigeration required before or after reconstitution)

  • Comes with BD SafetyGlideTM syringes for injection (with needle attached) (orange cap)

EGRIFTA WRTM was designed for simpler daily administration, thereby reducing the burden of treatment.

EGRIFTA WRTM supplies

Medication Box
Quantity Item
4 Single-patient use EGRIFTA WRTM 11.6 mg vials (1 vial per week for weekly mixing)
Injection Box
Quantity Item
1 30 mL bottle of Bacteriostatic Water for Injection (for weekly mixing)
4 Sterile BD Plastipak™ 3 mL syringes with needle attached (clear cap), for weekly mixing
33 Sterile BD SafetyGlide™ syringes with needle attached (orange cap), for daily injection
1 Box of 100 alcohol swabs

Each box contains supplies for 28 days of treatment.

Storing EGRIFTA WRTM

  • Store the Medication Box and Injection Box at room temperature at 68°F to 77°F (20°C to 25°C).
  • Keep the EGRIFTA WRTM vials out of the light.
  • Do not freeze or refrigerate EGRIFTA WRTM after it has been mixed with the Bacteriostatic Water for Injection.

Reconstitution and administration

One EGRIFTA WRTM 11.6 mg vial must be reconstituted weekly with 1.3 mL of Bacteriostatic Water for Injection to prepare seven daily injection doses.

The daily dose of EGRIFTA WRTM is 1.28 mg (0.16 mL of the reconstituted solution), administered once daily. Each vial provides seven consecutive daily injections.

Supporting your patients: Reconstitution essentials for EGRIFTA WRTM

Patients will need:

  • One 11.6 mg vial of EGRIFTA WRTM (Medication Box)
  • One BD PlastipakTM 3 mL syringe with needle for mixing—clear cap (Injection Box)
  • One bottle of Bacteriostatic Water for Injection (Injection Box)
  • Alcohol swabs (Injection Box)

Draw Bacteriostatic Water

Using the BD PlastipakTM 3 mL syringe (clear cap), draw 1.5 mL of Bacteriostatic Water for Injection from the bottle. This syringe is dedicated to weekly mixing.

Push the plunger up slowly to remove 0.2 mL of excess water and air out of the syringe and align the top rim of the plunger to the 1.3 mL mark.

The Bacteriostatic Water for Injection bottle should be placed back in the Injection Box for the next weekly mixing.

Inject water into the EGRIFTA WRTM vial

Insert the needle into the EGRIFTA WRTM vial, then push the plunger down to empty the syringe, allowing water to mix with the powder.

Swirl the solution

Instruct patients not to shake the vial. Instead, gently swirl the vial until the powder fully dissolves, resulting in a clear, colorless solution.

Check the solution

If the solution remains cloudy, discolored, or contains particles, patients should discard the vial and contact their healthcare provider or THERA patient support®.

Supporting your patients: Injection essentials for EGRIFTA WRTM

Patients will need:

  • Mixed and clear EGRIFTA WRTM solution from weekly mixing
  • One SafetyGlideTM syringe with needle for injection—orange cap (Injection Box)
  • Alcohol swabs (Injection Box)

Draw solution from the vial

Insert the BD SafetyGlideTM syringe (orange cap) into the vial and pull the plunger to the 0.18 mL mark. The daily dose is withdrawn from the same vial for 7 consecutive days.

Gently tap the syringe to force any air bubbles to rise to the top.

Adjust volume

Slowly push the plunger up to remove air and excess liquid until 0.16 mL mark is reached.

Inject EGRIFTA WRTM

The recommended injection site is the abdomen, avoiding scar tissue, bruises, hard bumps from previous injections, the belly button, or areas within 2 inches of the belly button.

Advise patients to rotate the site for each injection.

Step-by-Step Administration Video

This video was designed to be a step-by-step guide to help your patients learn how to mix and inject EGRIFTA WRTM.

coming soon

For complete instructions, read the full Instructions for Use

Download

Resources

Access dosing and administration resources for you and your patients.

Step-by-Step Administration Guide

Provide your patients with step-by-step instructions on how to mix and inject EGRIFTA WRTM.

Step-by-Step Administration Video

A detailed video walkthrough for preparing and administering EGRIFTA WRTM will be available shortly. Please check back soon for updates.

Our THERA patient support® Nurse Navigators can enhance your patients’ experience and promote treatment adherence.

Explore THERA patient support® program resources.

References:

  1. Theratechnologies Inc. EGRIFTA WRTM (tesamorelin) for injection Prescribing Information. March, 2025.
  2. Theratechnologies Inc. EGRIFTA WRTM (tesamorelin) for injection Instructions for Use. March, 2025.

Let’s keep in touch

Enter your contact details to stay up to date with the latest developments from Theratechnologies.

By clicking the “Sign up” button below, I consent to receiving communications from Theratechnologies.

* Mandatory field.

Thank You for Signing Up!

We look forward to keeping you informed with the latest news and updates from Theratechnologies.

IMPORTANT SAFETY INFORMATION ABOUT EGRIFTA WRTM (TESAMORELIN) FOR INJECTION

Indication

EGRIFTA WRTM is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.

Limitations of Use:

  • The impact and safety of EGRIFTA WRTM on cardiovascular health has not been studied.
  • EGRIFTA WRTM is not indicated for weight loss management.
  • It is not known whether taking EGRIFTA WRTM helps improve compliance with anti-retroviral medications.

Contraindications:

Do not use EGRIFTA WRTM if patient:

  • Has a pituitary gland tumor, has had pituitary gland surgery, has other problems related to their pituitary gland, or has had radiation treatment to their head or a head injury.
  • Has active cancer.
  • Is allergic to tesamorelin or any of the ingredients in EGRIFTA WRTM.
  • Is pregnant or planning to become pregnant.

Warnings and Precautions

  • Increased risk of neoplasms: Preexisting malignancy should be inactive and its treatment complete prior to starting EGRIFTA WRTM. EGRIFTA WRTM should be discontinued if the patient has evidence of recurrent malignancy.
  • Elevated IGF-1: Regularly monitor IGF-1 levels in all patients during EGRIFTA WRTM therapy. Consider discontinuing in patients with persistent elevations (e.g., >3 SDS).
  • Fluid retention: May include edema, arthralgia, and carpal tunnel syndrome.
  • Glucose intolerance or diabetes mellitus: May develop with EGRIFTA WRTM treatment. Evaluate glucose status prior to and during therapy with EGRIFTA WRTM.
  • Hypersensitivity reactions: Advise patients to seek immediate medical attention if suspected.
  • Injection site reactions: Advise patients to rotate sites to different areas of the abdomen to decrease injection site reactions.
  • Increased mortality in patients with acute critical illness: Consider discontinuation in critically ill patients.

Drug Interactions

  • EGRIFTA WRTM had no significant impact on the pharmacokinetic profiles of simvastatin in healthy subjects.
  • Monitor patients for potential interactions when administering EGRIFTA WRTM in combination with other drugs known to be metabolized by CYP450 liver enzyme.
  • Patients on glucocorticoids may require dosage adjustment upon initiation of EGRIFTA WRTM.

Use in Specific Populations

  • Lactation: Mothers should not breastfeed if they receive EGRIFTA WRTM.
  • Pediatric use: Safety and effectiveness in pediatric patients have not been established.
  • Geriatric use: There is no information on the use of EGRIFTA WRTM in patients greater than 65 years of age.

Adverse Reactions

The most commonly reported adverse reactions include injection site reactions, arthralgia, pain in extremity, myalgia, and peripheral edema.

For complete disclosure of EGRIFTA WRTM product information, please read the Full Prescribing Information, Patient Information, and Patient Instructions for Use.

For more information about EGRIFTA WRTM, contact THERA patient support® program toll-free at 1-833-23THERA (1-833-238-4372). To report suspected adverse reactions, contact THERA patient support® program or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.